Coherus Oncology (CHRS) EPS (Basic) Growth (3y) (2016 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) EPS (Basic) Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | 35.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35.26% |
| Mar 31, 2026 | 33.50% |
| Dec 31, 2025 | 24.89% |
| Sep 30, 2025 | 35.03% |
| Jun 30, 2025 | 81.38% |
| Mar 31, 2025 | 26.78% |
| Dec 31, 2024 | 9.95% |
| Sep 30, 2024 | 42.37% |
| Jun 30, 2024 | 34.24% |
| Mar 31, 2024 | 33.59% |
| Dec 31, 2023 | -102.03% |
| Sep 30, 2023 | -44.20% |
| Jun 30, 2023 | -36.78% |
| Mar 31, 2023 | -57.38% |
| Dec 31, 2022 | -49.58% |
| Sep 30, 2022 | -52.88% |
| Jun 30, 2022 | -57.49% |
| Mar 31, 2022 | -62.60% |
| Dec 31, 2021 | 14.29% |
| Sep 30, 2021 | 17.46% |